Daniel Thistlethwaite, MD
Psychiatry · South Charleston, WVNPI 1518083328
Payments from drug & device makers
Across 1,176 payments — averaging $397.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$119K
- Otsuka America Pharmaceutical, Inc.$110K
- AbbVie$103K
- Axsome Therapeutics, Inc.$71K
- Alkermes, Inc.$49K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- plus $7K from 25 others
What the payments were for
- Consulting fees$42,7109%
- Speaking & faculty fees$369,50679%
- Travel & lodging$32,7897%
- Food & beverage$21,9895%
- Education$5210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 197 | $118,916 |
| Otsuka America Pharmaceutical, Inc. | 179 | $109,529 |
| AbbVie(2 entities) | 244 | $103,266 |
| Axsome Therapeutics, Inc. | 80 | $70,635 |
| Alkermes, Inc. | 81 | $48,610 |
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $9,730 |
| Teva Pharmaceuticals USA, Inc. | 77 | $1,468 |
| Harmony Biosciences LLC | 42 | $831 |
| Lundbeck LLC | 50 | $804 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $580 |
| Brainsway USA Inc | 7 | $536 |
| Corium, LLC | 17 | $359 |
| Sunovion Pharmaceuticals Inc. | 7 | $333 |
| Tris Pharma Inc | 14 | $299 |
| Neurocrine Biosciences, Inc. | 15 | $269 |
| E.r. Squibb & Sons, L.L.C. | 4 | $263 |
| Vanda Pharmaceuticals Inc. | 8 | $156 |
| Biogen | 3 | $126 |
| Shire North American Group Inc | 10 | $126 |
| Eisai Inc. | 7 | $123 |
| Jazz Pharmaceuticals Inc. | 6 | $113 |
| Avanir Pharmaceuticals, Inc. | 7 | $105 |
| Neos Therapeutics, LP | 5 | $82 |
| Merck | 4 | $68 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Indivior Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$189,295
- SPRAVATO$116,087
- REXULTI$106,841
- VRAYLAR$100,336
- Auvelity$69,237
- TRINTELLIX$8,750
- Brainsway Deep TMS$473
- LATUDA$123
How this compares
$467,515 in reported general payments places this provider in the 95th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 91 | $162,439 |
| SpravatoEsketamine Hcl | 77 | $108,714 |
| RexultiBrexpiprazole | 46 | $101,661 |
| TrintellixVortioxetine Hydrobromide | 118 | $100,623 |
| AustedoDeutetrabenazine | 13 | $95,362 |
| Invega SustennaPaliperidone Palmitate | 13 | $49,664 |
| CaplytaLumateperone Tosylate | 16 | $25,406 |
| QuviviqDaridorexant Hcl | 38 | $22,748 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 247 | $20,796 |
| BelsomraSuvorexant | 41 | $19,938 |
| Dyanavel XrAmphetamine | 27 | $13,932 |
| Aripiprazole | 165 | $12,028 |
| AzstarysSerdexmethylphen/Dexmethylphen | 18 | $7,466 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 145 | $5,262 |
| Vilazodone Hcl | 63 | $4,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $103,266 | $162,43991 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $118,916 | $158,37890 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $109,529 | $101,66146 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $9,730 | $100,623118 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,468 | $95,36213 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $580 | $25,40616 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $30 | $22,74838 claims |
| MerckBelsomra | $68 | $19,93841 claims |
| Tris Pharma IncDyanavel Xr | $299 | $13,93227 claims |
| Corium, LLCAzstarys | $359 | $7,46618 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $1,630178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in South Charleston
- Amy WehrleSouth Charleston$9K
- Russell VoltinSouth Charleston$7K
- Alexander OtellinSouth Charleston$4K
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$176K
- Shahnoor KhanMartinsburg$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.